Phase 3 Readout

TNGX: Phase 3 Topline: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of A

Name: Phase 3 Topline: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of A
Start: 2029-08-31
End: 2029-08-31

August 31, 2029 · mfolfirinox. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: August 31, 2029
Company: Tango Therapeutics, Inc. (TNGX)
Drug: mfolfirinox

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of A

August 31, 2029

TNGX overview →

Company: Tango Therapeutics, Inc. (TNGX)
Drug: mfolfirinox
Indication: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma